Ovation Receives $1.5M In Funding And Launches Collaboration With iGeneTrain

May 24, 2017 | Ovation announced today the receipt of $1.5 million in funding from StageDotO, and existing investors, including Longfellow Ventures. The company will use the funds to continue the development of its next-generation scientific data-layer-as-a-service platforms, built to accelerate the progress of life science by improving how the story of scientific data is told. Ovation also announced a partnership with iGeneTRAiN to use Ovation Research to maximize collaboration capabilities across iGeneTRAiN’s transplant consortium. The announcement was made today at the 2017 BioIT World Conference and Expo.

The International Genetics & Translational Research in Transplantation Network (iGeneTRAiN) is a multi-institutional team of transplant surgeons and scientists co-led by researchers from the Perelman School of Medicine at the University of Pennsylvania, who have come together to investigate the genetic factors behind transplant successes and failures. iGeneTRAiN will use Ovation Research Pro to facilitatie the integration of genomic and other omic datasets in over 48,000 samples from more than 30 studies, across 12 countries.

“The premise behind iGeneTRAiN is that better sharing and understanding of the global data on transplants and their genetic factors will improve outcomes. Our collaboration with Ovation will significantly improve and accelerate that process,“ said Brendan J. Keating, DPhil, an Assistant Professor in the Division of Transplantation, Dept of Surgery in the University of Pennsylvania in and co-founder of iGeneTRAiN.